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 Re: Akt Phosphorylation and 
Gefi tinib Effi cacy in Patients 
With Advanced Non – Small-Cell 
Lung Cancer 
 We found the study by Cappuzzo 
et al.  ( 1 ) to be very interesting, and we 
congratulate the authors on conducting 
this important clinical trial, which iden-
tifi ed factors that were predictive of re-
sponse to gefi tinib. Cappuzzo et al.  ( 1 ) 
designed the trial to assess the possible 
association between activation of epi-
dermal growth factor receptor (EGFR) 
pathway downstream signaling compo-
nents MAPK and Akt and response to 
gefi tinib in patients with non – small-cell 
lung cancer (NSCLC). 
 Every year, more than 1 million pa-
tients are diagnosed with NSCLC world-
wide. Most of the patients will be not 
curable by surgery. Consequently, even 
if a small percentage of patients would 
benefi t from a targeted agent such as 
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gefi tinib, it would have a major impact 
on care. However, the best strategy for 
selecting patients who will respond to 
gefi tinib is unclear. 
 The EGFR tyrosine kinase is still 
the only recognized target for gefi tinib. 
However, the downstream components 
MAPK and Akt are activated in response 
to EGFR and to many other receptors. 
We believe that EGFR expression should 
always be analyzed initially as a factor 
that is predictive of response to an agent 
targeting EGFR. Indeed, some somati-
cally acquired mutations in the EGFR 
gene are strongly associated with clinical 
responsiveness to gefi tinib  ( 2 , 3 ) . For ex-
ample, preliminary data from a mutation 
analysis of bronchioalveolar carcinoma 
(BAC)/adenocarcinoma tumors from pa-
tients enrolled in the SWOG 0126 trial 
showed that 43% of 14 patients had an 
EGFR mutation in exon 18, 19, or 21  ( 4 ) . 
The BAC histotype was associated with 
gefi tinib sensitivity. 
 An analysis of the relationship be-
tween EGFR mutations and activation of 
the downstream components should then 
clarify whether activation of MAPK 
and/or Akt is an independent factor 
that can increase the predictive value of 
EGFR mutations or whether activation 
of MAPK and/or Akt is just a less spe-
cifi c marker of a subgroup of gefi tinib-
responsive patients already selected by 
the analysis of EGFR itself. Thus, we 
are concerned about the missing data on 
lack of analysis of EGFR expression in 
the study by Cappuzzo et al.  ( 1 ) . 
 We are also concerned about the 
timing of the assessment for EGFR ex-
pression and MAPK and Akt activation 
in Cappuzzo et al.  ( 1 ) . It appears that 
most of the specimens were collected at 
the time of primary diagnosis, and that 
 patients were treated with gefi tinib after 
having received chemotherapy. We have 
found  ( 5 ) that chemotherapy can in-
duce EGFR expression in some  patients 
with EGFR-negative tumors. In this 
analysis, we evaluated EGFR expres-
sion on mediastinal lymph nodes and/or 
primary tumors before and after che-
motherapy in patients with stage IIIa/b
pN2/3 NSCLC. Before chemotherapy, 
six patients had EGFR-negative medias-
tinal lymph nodes and fi ve patients had 
EGFR-negative primary tumors. After 
chemotherapy, four of the six EGFR-
negative mediastinal lymph nodes and 
three of the fi ve EGFR-negative primary 
tumors were EGFR positive. Although 
this observation was very preliminary, it 
raised the possibility that systemic che-
motherapy can change EGFR expres-
sion and activation of its downstream 
pathway. This possibility could explain 
the two responses observed among Akt-
 negative tumors in Cappuzzo et al.  ( 1 ) . 
 A prospective study is needed to 
 assess the relationship between EGFR 
mutations and activation of downstream 
pathway components. The identifi cation 
of a profi le that is strongly predictive of 
the response to EGFR targeting agents 
will be important to increase the clinical 
impact of these agents in clinical care. 
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 none RESPONSE 
 Gefi tinib is a tyrosine kinase  inhibitor 
(TKI) of the epidermal growth factor 
receptor (EGFR). Although approxi-
mately 10% of non – small-cell lung 
cancer (NSCLC) patients who received 
gefi tinib had a dramatic response and 
increased long-term survival, patients 
not selected for any biologic character-
istic who received the drug as a fi rst-line 
therapy in combination with standard 
chemotherapy had no survival advan-
tage  ( 1 , 2 ) . The mechanisms underlying 
gefi tinib sensitivity have recently been 
discovered. It is now known that spe-
cifi c EGFR gene mutations can confer 
a gefi tinib-sensitive phenotype  ( 3 ) , that 
a consequence of these mutations is the 
activation of the antiapoptotic protein 
Akt  ( 4 ) , and that patients whose tumors 
have activated Akt are more sensitive to 
the drug than patients whose tumors do 
not  ( 5 ) . In December 2004, AstraZeneca 
announced the results of the ISEL trial, 
a phase III randomized study compar-
ing gefi tinib with placebo in pretreated 
NSCLC patients. In this trial, the sur-
vival benefi t observed in patients who 
received gefi tinib was not statistically 
signifi cant (hazard ratio of death = 0.89, 
 P = .11). The negative results of the ISEL 
trial and those of all trials using a TKI in 
combination with chemotherapy clearly 
indicate that it is not possible to propose 
a TKI to all patients with NSCLC and 
that TKIs should be offered to patients 
selected for the presence of the drug 
target, i.e., the presence of EGFR gene 
mutations or amplifi cation. Unfortu-
nately, the problem of patient selection 
is further complicated because different 
mechanisms are involved in TKI sensi-
tivity. For example, erlotinib was shown 
to improve survival compared with pla-
cebo in pretreated patients  ( 6 ) , but ben-
efi t was not confi ned to responders or to 
patients with EGFR gene mutations. 
 For several years, we have focused 
on identifying a biological predictor of 
gefi tinib sensitivity. We observed that 
patients whose tumors had activated Akt 
had a statistically signifi cantly higher re-
sponse rate and disease control rate and 
longer time to progression than patients 
whose tumors did not have activated Akt, 
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but the difference in overall survival was 
not statistically signifi cant  ( 5 ) . Because 
several receptors can activate Akt, we hy-
pothesized that patients with Akt activa-
tion would be sensitive to the inhibitory 
effect of gefi tinib only if Akt activation 
was sustained by an EGFR-dependent 
mechanism. Therefore, as correctly sug-
gested by de Braud et al., we recently 
performed EGFR and Akt analyses in a 
large cohort of NSCLC  patients treated 
with gefi tinib. The results of this study 
confi rm that Akt activation is required 
for gefi tinib sensitivity in patients with 
EGFR-positive tumors, irrespective of 
the method used for EGFR assessment, 
and support the idea of analyzing Akt 
status to aid in identifying  patients for 
TKI therapy. 
 De Braud et al. also raised the issue 
of timing of Akt assessment. Although 
no trial to date has specifi cally addressed 
this question, preclinical data suggest that 
NSCLC tumors become more dependent 
on the EGFR signalling pathway and 
more sensitive to EGFR blocking strate-
gies as they are exposed to different che-
motherapies  ( 7 ) . Therefore, I agree that, 
because of the possible effects of previ-
ous therapies on EGFR pathways, it is 
possible that our results underestimated 
the true association between the molecu-
lar variables and response to gefi tinib. 
 FEDERICO  CAPPUZZO 
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